Ask AI
ProCE Banner Activity

Expert Insights on Schizophrenia Treatment: Your Questions Answered

Clinical Thought

Read this commentary sharing practical strategies and clinical considerations for navigating the evolving landscape of schizophrenia treatment, from the enduring role of haloperidol to emerging agents like xanomeline/trospium. By exploring individualized approaches to persistent symptoms, medication combinations, and metabolic management, healthcare professionals can tailor treatment more precisely to patient needs.

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Practicing Clinicians Exchange (PCE) 

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

Target Audience

This activity is intended for healthcare professionals caring for patients with schizophrenia including psychiatrists, physicians, nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the characteristics of novel and emerging therapeutic agents for schizophrenia beyond antidopaminergic antipsychotics, including mechanisms of action and pharmacokinetics

  • Differentiate evidence for efficacy and safety profiles of novel agents used in the treatment of schizophrenia

  • Explain the potential of novel antipsychotics in transforming clinical practice by addressing unmet needs of current schizophrenia treatments

Disclosure

Primary Author

Joseph F. Goldberg, MD: consultant/advisor/speaker: AbbVie, Alkermes, Alvogen, Axsome, Bristol Myers Squibb, Genomind, Luye, Neumora, Otsuka.